Recombinant Human Soluble Thrombomodulin Treatment for Acute Exacerbation of Idiopathic Pulmonary Fibrosis: A Retrospective Study | Zendy

Takuma Isshiki | Zendy; Susumu Sakamoto | Zendy; Arisa Kinoshita | Zendy; Keishi Sugino | Zendy; Atsuko Kurosaki | Zendy; Sakae Homma | Zendy

Open Access

Recombinant Human Soluble Thrombomodulin Treatment for Acute Exacerbation of Idiopathic Pulmonary Fibrosis: A Retrospective Study

Author(s) -

Takuma Isshiki,

Susumu Sakamoto,

Arisa Kinoshita,

Keishi Sugino,

Atsuko Kurosaki,

Sakae Homma

Publication year - 2015

Publication title -

respiration

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.264

H-Index - 81

eISSN - 1423-0356

pISSN - 0025-7931

DOI - 10.1159/000369828

Subject(s) - medicine , exacerbation , idiopathic pulmonary fibrosis , retrospective cohort study , gastroenterology , lactate dehydrogenase , hypersensitivity pneumonitis , lung , biochemistry , chemistry , enzyme

Acute exacerbation of idiopathic pulmonary fibrosis (AE-IPF) can be fatal, and abnormalities in the coagulation system of patients with AE-IPF have been reported. Recombinant human soluble thrombomodulin (rhTM) forms a complex with thrombin to inactivate coagulation. It also inhibits high-mobility group box protein 1 (HMGB-1), which results in the suppression of inflammation.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research